Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Travere Therapeutics
TVTX
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$14.38
-0.13
-0.86%
Last update: 10:12 AM
15 minutes delayed
Get Report
Comment
Travere Therapeutics (TVTX) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Travere Therapeutics (NASDAQ:TVTX) Stock
Travere Therapeutics Stock (NASDAQ: TVTX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, September 13, 2024
JP Morgan Maintains Overweight on Travere The...
Benzinga Newsdesk
Tuesday, September 10, 2024
Canaccord Genuity Maintains Buy on Travere Th...
Benzinga Newsdesk
Monday, September 09, 2024
Travere Therapeutics shares are trading highe...
Benzinga Newsdesk
This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Avi Kapoor
Guggenheim Upgrades Travere Therapeutics to B...
Benzinga Newsdesk
Friday, September 06, 2024
Analyst Ratings For Travere Therapeutics
Benzinga Insights
Citigroup Maintains Buy on Travere Therapeuti...
Benzinga Newsdesk
Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday
Avi Kapoor
B of A Securities Maintains Buy on Travere Th...
Benzinga Newsdesk
NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday
Avi Kapoor
Travere Therapeutics shares are trading highe...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Travere ...
Benzinga Newsdesk
Thursday, September 05, 2024
Trading Halt: Halt status updated at 7:05:00 ...
Benzinga Newsdesk
Travere Says FDA Has Granted Full Approval To...
Benzinga Newsdesk
Trading Halt: Halted at 4:34:47 p.m. ET - Tra...
Benzinga Newsdesk
Tuesday, August 13, 2024
JP Morgan Maintains Overweight on Travere The...
Benzinga Newsdesk
Monday, August 05, 2024
HC Wainwright & Co. Maintains Buy on Travere ...
Benzinga Newsdesk
Friday, August 02, 2024
Barclays Maintains Overweight on Travere Ther...
Benzinga Newsdesk
Expert Ratings For Travere Therapeutics
Benzinga Insights
Piper Sandler Maintains Neutral on Travere Th...
Benzinga Newsdesk
Wedbush Maintains Outperform on Travere Thera...
Benzinga Newsdesk
Thursday, August 01, 2024
Travere Therapeutics Files Mixed Securities S...
Benzinga Newsdesk
Travere Therapeutics Q2 2024 Adj. EPS $(0.65)...
Benzinga Newsdesk
Wednesday, July 10, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Tuesday, July 09, 2024
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
Tuesday, May 07, 2024
HC Wainwright & Co. Reiterates Buy on Travere...
Benzinga Newsdesk
Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts
Benzinga Insights
Travere Therapeutics shares are trading highe...
Benzinga Newsdesk
Canaccord Genuity Maintains Buy on Travere Th...
Benzinga Newsdesk
Monday, May 06, 2024
Travere Therapeutics Q1 2024 Adj EPS $(1.51) ...
Benzinga Newsdesk
Wednesday, April 24, 2024
HC Wainwright & Co. Maintains Buy on Travere ...
Benzinga Newsdesk
CSL Vifor And Travere Therapeutics Granted Eu...
Benzinga Newsdesk
Friday, April 19, 2024
Reported Earlier, Travere Therapeutics And CC...
Benzinga Newsdesk
Wednesday, April 17, 2024
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
Benzinga Insights
Wedbush Reiterates Outperform on Travere Ther...
Benzinga Newsdesk
Wednesday, April 03, 2024
Travere Therapeutics To Present Abstracts On ...
Benzinga Newsdesk
Wednesday, March 27, 2024
Guggenheim Downgrades Travere Therapeutics to...
Benzinga Newsdesk
Wednesday, March 13, 2024
Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights
Benzinga Insights
HC Wainwright & Co. Maintains Buy on Travere ...
Benzinga Newsdesk
Monday, March 11, 2024
Travere Therapeutics Submits Supplemental New...
Benzinga Newsdesk
Friday, February 23, 2024
Travere Therapeutics And CSL Vifor Announced ...
Benzinga Newsdesk
Friday, February 16, 2024
Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings)
Benzinga Insights
Wedbush Reiterates Outperform on Travere Ther...
Benzinga Newsdesk
Thursday, February 15, 2024
Travere Therapeutics Q4 Adj EPS $(0.94) Beats...
Benzinga Newsdesk
Earnings Scheduled For February 15, 2024
Benzinga Insights
Wednesday, February 14, 2024
Earnings Preview For Travere Therapeutics
Benzinga Insights
Thursday, January 25, 2024
Travere Therapeutics Announces Licensing Agre...
Benzinga Newsdesk
Thursday, January 18, 2024
Cracking The Code: Understanding Analyst Reviews For Travere Therapeutics
Benzinga Insights
Piper Sandler Maintains Neutral on Travere Th...
Benzinga Newsdesk
Monday, January 08, 2024
Travere Therapeutics shares are trading highe...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch